Form 4: AtriCure Director Shlomo Nachman Reports Acquisition and Disposal of Common Stock

Director Shlomo Nachman reports acquiring 5,401 shares of AtriCure common stock through a restricted stock award and disposing of 18,511 shares.

Summary

• On May 19, 2025, Shlomo Nachman, a director of AtriCure, Inc., reported transactions involving the company's common stock.
• Nachman acquired 5,401 shares through a restricted stock award under the 2023 Stock Incentive Plan, with the shares vesting on the one-year anniversary of the grant date.
• The acquisition price was $0.
• Nachman also disposed of 18,511 shares.
• Following these transactions, Nachman directly owns 18,511 shares of AtriCure common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports transactions without providing any explicit positive or negative outlook. The disposal of shares could be seen as slightly negative, but without further context, it's difficult to assess the overall impact.

Positives

• The acquisition of shares via a restricted stock award aligns the director's interests with the company's long-term performance.

Negatives

• The disposal of 18,511 shares by a director could be interpreted negatively by investors, although the reason for disposal is not disclosed.

Risks

• The document does not provide context for the disposal of shares, which could lead to speculation and uncertainty among investors.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key individuals within a company.

Stakeholder Impact

• Shareholders may react to the reported transactions, particularly the disposal of shares, depending on their interpretation of the director's actions.

Key Dates

Keywords

AtriCure, Director, Nachman, Stock, Acquisition, Disposal, Restricted Stock Award, Form 4